Two years of cyclophosphamide and 5‐fluorouracil as adjuvant chemotherapy for stage II and III breast carcinoma

E. Caceres, S. Valdivia, M. Cotrina, M. Lingan, L. Leon, M. Gamboa, L. Olivares, M. Moran

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The results after 6 years of a prospective clinical trial of adjuvant chemotherapy with a regimen of two drugs—cyclophosphamide and 5‐fluorouracil (CF)— for 2 years in 97 women with stage II or III breast cancer are reported. Eligible patients were free from distant metastases. All patients began adjuvant therapy within 4 weeks of surgery; therapy consisted of radical, modified, or extended radical mastectomy. No postoperative radiotherapy was given. The results are compared with a historical control group from previous consecutive patients treated by surgery alone. Patients were stratified by age (younger than 50 or older than or equal to 50) and nodal status (one to three positive axillary nodes vs. four or more positive nodes). The estimated 6‐year survival was 60% for CF patients vs. 31% for control patients (P = 0.001). The estimated 6‐year disease‐free survival was 53.6 and 30.3% for CF and control, respectively (P = 0.007). There was a trend toward longer disease‐free survival (DFS) and survival (S) in patients treated with CF, but this was not significant in all the subgroups. Disease‐free survival was statistically significant in the subgroup of women ≥ 50 years old with one to three positive nodes (P = 0.038); survival in the patients ≤ 49 years old with four or more positive nodes (P = 0.0036); and in patients ≥ 50 years old with one to three lymph nodes involvement (P = 0.038).

Original languageEnglish (US)
Pages (from-to)169-174
Number of pages6
JournalJournal of Surgical Oncology
Volume39
Issue number3
DOIs
StatePublished - Jan 1 1988

Fingerprint

Adjuvant Chemotherapy
Cyclophosphamide
Breast Neoplasms
Survival
Extended Radical Mastectomy
Modified Radical Mastectomy
Radiotherapy
Lymph Nodes
Clinical Trials
Neoplasm Metastasis
Control Groups
Therapeutics

Keywords

  • Disease‐free survival
  • lymph node involvement

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Two years of cyclophosphamide and 5‐fluorouracil as adjuvant chemotherapy for stage II and III breast carcinoma. / Caceres, E.; Valdivia, S.; Cotrina, M.; Lingan, M.; Leon, L.; Gamboa, M.; Olivares, L.; Moran, M.

In: Journal of Surgical Oncology, Vol. 39, No. 3, 01.01.1988, p. 169-174.

Research output: Contribution to journalArticle

Caceres, E, Valdivia, S, Cotrina, M, Lingan, M, Leon, L, Gamboa, M, Olivares, L & Moran, M 1988, 'Two years of cyclophosphamide and 5‐fluorouracil as adjuvant chemotherapy for stage II and III breast carcinoma', Journal of Surgical Oncology, vol. 39, no. 3, pp. 169-174. https://doi.org/10.1002/jso.2930390307
Caceres, E. ; Valdivia, S. ; Cotrina, M. ; Lingan, M. ; Leon, L. ; Gamboa, M. ; Olivares, L. ; Moran, M. / Two years of cyclophosphamide and 5‐fluorouracil as adjuvant chemotherapy for stage II and III breast carcinoma. In: Journal of Surgical Oncology. 1988 ; Vol. 39, No. 3. pp. 169-174.
@article{72ee5e69e7a84cea91fda9dedcef66d0,
title = "Two years of cyclophosphamide and 5‐fluorouracil as adjuvant chemotherapy for stage II and III breast carcinoma",
abstract = "The results after 6 years of a prospective clinical trial of adjuvant chemotherapy with a regimen of two drugs—cyclophosphamide and 5‐fluorouracil (CF)— for 2 years in 97 women with stage II or III breast cancer are reported. Eligible patients were free from distant metastases. All patients began adjuvant therapy within 4 weeks of surgery; therapy consisted of radical, modified, or extended radical mastectomy. No postoperative radiotherapy was given. The results are compared with a historical control group from previous consecutive patients treated by surgery alone. Patients were stratified by age (younger than 50 or older than or equal to 50) and nodal status (one to three positive axillary nodes vs. four or more positive nodes). The estimated 6‐year survival was 60{\%} for CF patients vs. 31{\%} for control patients (P = 0.001). The estimated 6‐year disease‐free survival was 53.6 and 30.3{\%} for CF and control, respectively (P = 0.007). There was a trend toward longer disease‐free survival (DFS) and survival (S) in patients treated with CF, but this was not significant in all the subgroups. Disease‐free survival was statistically significant in the subgroup of women ≥ 50 years old with one to three positive nodes (P = 0.038); survival in the patients ≤ 49 years old with four or more positive nodes (P = 0.0036); and in patients ≥ 50 years old with one to three lymph nodes involvement (P = 0.038).",
keywords = "Disease‐free survival, lymph node involvement",
author = "E. Caceres and S. Valdivia and M. Cotrina and M. Lingan and L. Leon and M. Gamboa and L. Olivares and M. Moran",
year = "1988",
month = "1",
day = "1",
doi = "10.1002/jso.2930390307",
language = "English (US)",
volume = "39",
pages = "169--174",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Two years of cyclophosphamide and 5‐fluorouracil as adjuvant chemotherapy for stage II and III breast carcinoma

AU - Caceres, E.

AU - Valdivia, S.

AU - Cotrina, M.

AU - Lingan, M.

AU - Leon, L.

AU - Gamboa, M.

AU - Olivares, L.

AU - Moran, M.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - The results after 6 years of a prospective clinical trial of adjuvant chemotherapy with a regimen of two drugs—cyclophosphamide and 5‐fluorouracil (CF)— for 2 years in 97 women with stage II or III breast cancer are reported. Eligible patients were free from distant metastases. All patients began adjuvant therapy within 4 weeks of surgery; therapy consisted of radical, modified, or extended radical mastectomy. No postoperative radiotherapy was given. The results are compared with a historical control group from previous consecutive patients treated by surgery alone. Patients were stratified by age (younger than 50 or older than or equal to 50) and nodal status (one to three positive axillary nodes vs. four or more positive nodes). The estimated 6‐year survival was 60% for CF patients vs. 31% for control patients (P = 0.001). The estimated 6‐year disease‐free survival was 53.6 and 30.3% for CF and control, respectively (P = 0.007). There was a trend toward longer disease‐free survival (DFS) and survival (S) in patients treated with CF, but this was not significant in all the subgroups. Disease‐free survival was statistically significant in the subgroup of women ≥ 50 years old with one to three positive nodes (P = 0.038); survival in the patients ≤ 49 years old with four or more positive nodes (P = 0.0036); and in patients ≥ 50 years old with one to three lymph nodes involvement (P = 0.038).

AB - The results after 6 years of a prospective clinical trial of adjuvant chemotherapy with a regimen of two drugs—cyclophosphamide and 5‐fluorouracil (CF)— for 2 years in 97 women with stage II or III breast cancer are reported. Eligible patients were free from distant metastases. All patients began adjuvant therapy within 4 weeks of surgery; therapy consisted of radical, modified, or extended radical mastectomy. No postoperative radiotherapy was given. The results are compared with a historical control group from previous consecutive patients treated by surgery alone. Patients were stratified by age (younger than 50 or older than or equal to 50) and nodal status (one to three positive axillary nodes vs. four or more positive nodes). The estimated 6‐year survival was 60% for CF patients vs. 31% for control patients (P = 0.001). The estimated 6‐year disease‐free survival was 53.6 and 30.3% for CF and control, respectively (P = 0.007). There was a trend toward longer disease‐free survival (DFS) and survival (S) in patients treated with CF, but this was not significant in all the subgroups. Disease‐free survival was statistically significant in the subgroup of women ≥ 50 years old with one to three positive nodes (P = 0.038); survival in the patients ≤ 49 years old with four or more positive nodes (P = 0.0036); and in patients ≥ 50 years old with one to three lymph nodes involvement (P = 0.038).

KW - Disease‐free survival

KW - lymph node involvement

UR - http://www.scopus.com/inward/record.url?scp=0023768630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023768630&partnerID=8YFLogxK

U2 - 10.1002/jso.2930390307

DO - 10.1002/jso.2930390307

M3 - Article

C2 - 3054335

AN - SCOPUS:0023768630

VL - 39

SP - 169

EP - 174

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 3

ER -